By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mitochondrial DNA diagnostic test firm Mitomics today announced that QDx Pathology Services will develop, market, and process the QPredict Prostate Mitomic Test.

The test will be based on Mitomics' Prostate Core Mitomic Test, which Mitomics launched in March. Under the non-exclusive agreement, QDx Pathology will leverage its network of pathologists, urologists, and processing centers to expand the availability of the technology in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.